Great Lakes Advisors LLC Lowers Stock Position in Glaukos Co. (NYSE:GKOS)

Great Lakes Advisors LLC lessened its stake in shares of Glaukos Co. (NYSE:GKOS) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 113,301 shares of the medical instruments supplier’s stock after selling 1,259 shares during the quarter. Great Lakes Advisors LLC’s holdings in Glaukos were worth $16,988,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. IFP Advisors Inc purchased a new position in Glaukos during the fourth quarter worth about $43,000. Asset Planning Inc purchased a new position in Glaukos during the fourth quarter worth about $90,000. Harvest Fund Management Co. Ltd boosted its stake in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 860 shares during the period. SBI Securities Co. Ltd. purchased a new position in Glaukos during the fourth quarter worth about $153,000. Finally, Smartleaf Asset Management LLC boosted its stake in Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock worth $164,000 after buying an additional 807 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Activity at Glaukos

In related news, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,744 shares of company stock valued at $2,504,131 in the last ninety days. Insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

GKOS has been the subject of several recent research reports. Stifel Nicolaus raised their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. UBS Group initiated coverage on shares of Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective for the company. BTIG Research raised their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, Wells Fargo & Company raised their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Stock Up 5.5 %

Shares of Glaukos stock opened at $103.13 on Thursday. Glaukos Co. has a 52-week low of $84.08 and a 52-week high of $163.71. The company has a 50 day moving average of $143.84 and a 200 day moving average of $138.41. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.83 billion, a P/E ratio of -35.93 and a beta of 0.99.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. As a group, research analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.